베타
임상 레이더 AI
임상시험 NCT04210115은(는) 식도 편평 세포암 (ESCC), 위식도 접합부 암 (GEJC), 식도 선암 (EAC)에 대해 진행중, 모집종료 상태입니다. 모든 세부 정보를 보려면 임상시험 레이더 카드 뷰와 AI 발견 도구를 확인하거나 여기에서 무엇이든 물어보세요.
하나의 임상시험이 필터 기준과 일치합니다.
카드 뷰
검색으로 돌아가기

Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) 3상 703 전체 생존기간

진행중, 모집종료
임상시험 세부 정보는 주로 영어로 제공됩니다. 하지만 임상 레이더 AI가 도와드릴 수 있습니다! '임상시험 설명'를 클릭하여 선택한 언어로 임상시험 정보를 확인하고, 이에 대해 AI와 논의해 보세요.
임상시험 NCT04210115은(는) 치료을(를) 알아보기 위한 연구입니다. 이 연구는 식도 편평 세포암 (ESCC), 위식도 접합부 암 (GEJC), 식도 선암 (EAC)에 대해 진행되며, 3상 중재연구으로 현재 상태는 진행중, 모집종료입니다. 연구는 2020년 2월 28일에 시작되어 703명의 참여자를 모집하고 있습니다. 머크이(가) 진행하며, 2027년 2월 1일까지 완료될 예정입니다. ClinicalTrials.gov의 가장 최근 정보는 2024년 11월 15일에 갱신되었습니다.
간단한 개요

The purpose of this study is to assess the efficacy and safety of treatment with definitive chemoradiotherapy (dCRT) + pembrolizumab (MK-3475) compared to treatment with dCRT + placebo with respect to Event-free Survival (EFS) and Overall Survival (OS) in:

  • participants whose tumors express Programmed Death-Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10
  • participants whose tumors express PD-L1 CPS ≥1
  • all par...
더 보기
상세한 설명

Participants receive pembrolizumab or placebo PLUS one of two chemotherapy regimens PLUS radiation therapy for up to approximately one year. The chemotherapy regimens are either:

  • FP (5-fluorouracil \[5-FU\] + cisplatin) or
  • FOLFOX (5-FU + oxaliplatin + leucovorin or levoleucovorin).
공식 제목

A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)

질환명
식도 편평 세포암 (ESCC)위식도 접합부 암 (GEJC)식도 선암 (EAC)
출판물
이 임상시험에 대해 발표된 과학 논문 및 연구 자료.
기타 연구 식별자
  • 3475-975
  • MK-3475-975 (기타 식별자) (MSD)
  • KEYNOTE-975 (기타 식별자) (MSD)
  • PHRR200210-002490 (등록 식별자) (PHRR)
  • 205261 (등록 식별자) (Japic-CTI)
  • 2022-501531-16 (등록 식별자) (EU CT)
  • 2019-002006-51 (EudraCT 번호)
NCT 번호
NCT04210115
실제 연구 시작일
2020-02-28
최신 업데이트 게시
2024-11-15
예상 연구 완료일
2027-02-01
계획된 등록 인원
703
연구종류
중재연구
단계/상
3상
상태
진행중, 모집종료
키워드
Programmed Cell Death-1 (PD1, PD-1)
Programmed Death-Ligand 1 (PDL1, PD-L1)
Programmed Death-Ligand 2 (PDL2, PD-L2)
주요 목적
치료
설계 할당
무작위배정
중재 모델
평행설계
맹검 (마스킹)
삼중맹검
시험군 / 개입
참가자 그룹/시험군개입/치료
실험적Pembrolizumab+FP or FOLFOX Therapy+Radiotherapy
Participants receive pembrolizumab 200 mg on Day 1 of each 3-week cycle for 8 cycles followed by pembrolizumab 400 mg on Day 1 of each 6-week cycle for 5 cycles PLUS either: * FP therapy: cisplatin 75 mg/m\^2 on Day 1 of Weeks 1, 5, 8 and 11 PLUS 5-fluorouracil (5-FU)\] 1000 mg/m\^2 per day on Days 1-4 of Weeks 1, 5, 8 and 11 OR 800 mg/m\^2/day on each of Days 1-5 at Weeks 1, 5, 8, and 11 PLUS radiotherapy (either 5...더 보기
pembrolizumab
IV infusion
cisplatin
IV infusion
5-FU
IV infusion
방사선 요법
external radiation
leucovorin
IV infusion
levoleucovorin
IV infusion
oxaliplatin
IV infusion
위약 대조군Placebo+FP or FOLFOX Therapy+Radiotherapy
Participants receive placebo on Day 1 of each 3-week cycle for 8 cycles followed by placebo on Day 1 of each 6-week cycle for 5 cycles PLUS either: * FP therapy: cisplatin 75 mg/m\^2 on Day 1 of Weeks 1, 5, 8 and 11 PLUS 5-FU 1000 mg/m\^2 per day on Days 1-4 of Weeks 1, 5, 8 and 11 OR 800 mg/m\^2/day on each of Days 1-5 at Weeks 1, 5, 8, and 11 PLUS radiotherapy (either 50 Gy in 25 fractions OR 60 Gy in 30 fractions...더 보기
위약
IV infusion
cisplatin
IV infusion
5-FU
IV infusion
방사선 요법
external radiation
leucovorin
IV infusion
levoleucovorin
IV infusion
oxaliplatin
IV infusion
주요결과변수
결과변수측정값 설명시간 범위
Event-free Survival (EFS)
EFS is defined as the time from randomization to an event defined as local, regional, or distant radiological recurrence as assessed by the investigator; clinical recurrence as assessed by the investigator with histopathologic confirmation (in the absence of radiological disease recurrence by investigator assessment); or death from any cause, whichever occurs first.
Up to ~60 months
Overall Survival (OS)
OS is defined as the time from randomization to death from any cause.
Up to ~72 months
이차결과변수
결과변수측정값 설명시간 범위
Number of participants with an adverse event (AE)
An AE is any untoward medical occurrence in a participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment.
Up to ~15 months
Number of participants discontinuing study treatment due to an adverse event (AE)
An AE is any untoward medical occurrence in a participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment.
Up to ~12 months
참여 도우미
적격성 기준

연령대
성인, 노인
최소 연령
18 Years
참여 가능한 성별
전체
  • Has histologically or cytologically confirmed diagnosis of CTX N+ M0 or cT2-T4a NX M0 ESCC, GEJC, EAC, or histologically or cytologically confirmed diagnosis of cTX N+ M1 cervical or upper thoracic esophageal carcinoma with supraclavicular lymph node metastases only
  • Is deemed suitable for dCRT
  • Is ineligible for curative surgery based on the documented opinion of a qualified medical/surgical/radiation oncologist.
  • Is not expected to require tumor resection during the course of the study
  • Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 within 3 days of the first dose of study treatment
  • Has adequate organ function
  • Male participants must use adequate contraception (a male condom plus partner use of an additional contraceptive method) unless confirmed to be azoospermic (vasectomized or secondary to medical cause) and refrain from donating sperm during the study treatment period and through 90 days after the last dose of chemotherapy
  • Female participants who are a Woman of Childbearing Potential (WOCBP) must use contraception that is highly effective (with a failure rate of <1% per year), with low user dependency, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle, during the study treatment period through 180 days after the last dose of chemotherapy or 120 days after the last dose of pembrolizumab, whichever is greater, and agree not to donate eggs to others or freeze/store for her own use for the purpose of reproduction during this period
  • Female participants must not be pregnant or breastfeeding

  • Has direct invasion of tumor into adjacent organs such as the aorta or trachea or has radiographic evidence of >90 degree encasement or invasion of a major blood vessel, or of intratumoral cavitation
  • Has had major surgery other than for insertion of a feeding tube, open biopsy, or significant traumatic injury within 28 days prior to randomization, or anticipates the need for major surgery during study treatment; participants with gastric or esophageal fistulae are excluded
  • Has had weight loss of >20% in the previous 3 months
  • Has had prior chemotherapy or radiotherapy for esophageal cancer
  • Has had a myocardial infarction within the past 6 months
  • Has symptomatic congestive heart failure
  • Has received prior therapy with an anti-programmed cell death-1 (anti-PD-1), anti-programmed cell death-ligand 1 (anti-PD-L1), or anti-programmed cell death-ligand 2 (anti-PD-L2) agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated protein 4 \[CTLA-4\], OX-40, CD137)
  • Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention; administration of killed vaccines is allowed
  • Has received any prior systemic anticancer therapy for esophageal cancer including investigational agents
  • Has not recovered from all adverse events (AEs) due to previous non-anticancer therapies to ≤Grade 1 or Baseline
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study treatment
  • Has a known additional malignancy that is progressing or has required active treatment within the past 3 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded from the study. Participants with localized prostate cancer that has undergone potentially curative treatment can be enrolled in the study.
  • Has severe hypersensitivity (≥Grade 3) to pembrolizumab, any of the study chemotherapy agents, or their excipients
  • Has an active autoimmune disease that has required systemic treatment in past 2 years
  • Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis
  • Has an active infection requiring systemic therapy
  • Has a known history of human immunodeficiency virus (HIV) infection
  • Has a known history of Hepatitis B or known active Hepatitis C virus infection
  • Has a known history of active tuberculosis (TB; Bacillus tuberculosis)
  • Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study treatment (180 days for participants receiving cisplatin who are breastfeeding)
  • Has had an allogeneic tissue/solid organ transplant
Merck Sharp & Dohme LLC logo머크707개의 진행 중인 임상시험 탐색 가능
연락처 정보가 없습니다.
170 27개국에 임상시험 장소

Jeonranamdo

Chonnam National University Hwasun Hospital ( Site 0625), Hwasun Gun, Jeonranamdo, 58128, South Korea

Kyonggi-do

National Cancer Center ( Site 0626), Goyang-si, Kyonggi-do, 10408, South Korea

Seoul

Asan Medical Center ( Site 0623), Songpagu, Seoul, 05505, South Korea
Severance Hospital Yonsei University Health System ( Site 0624), Seoul, 03722, South Korea
Samsung Medical Center ( Site 0622), Seoul, 06351, South Korea
Korea University Guro Hospital ( Site 0621), Seoul, 08308, South Korea

California

MemorialCare Health System - Long Beach Medical Center-Oncology ( Site 0691), Long Beach, California, 90806, United States

Georgia

Columbus Regional Research Institute ( Site 0047), Columbus, Georgia, 31904, United States

Kansas

University of Kansas Cancer Center ( Site 0023), Westwood, Kansas, 66205, United States
Cancer Center of Kansas ( Site 0058), Wichita, Kansas, 67214, United States

Louisiana

University Medical Center ( Site 0035), New Orleans, Louisiana, 70112, United States

Maryland

Greater Baltimore Medical Center ( Site 0031), Baltimore, Maryland, 21204, United States

Massachusetts

Dana Farber Cancer Center ( Site 0034), Boston, Massachusetts, 02215, United States

Michigan

Henry Ford Hospital ( Site 0685), Detroit, Michigan, 48202, United States

Missouri

University of Missouri ( Site 0688), Columbia, Missouri, 65212, United States

Nevada

Renown Regional Medical Center ( Site 0706), Reno, Nevada, 89502, United States

New Jersey

Rutgers Cancer Institute of New Jersey ( Site 0695), New Brunswick, New Jersey, 08903, United States

New York

Weill Cornell Medical College ( Site 0053), New York, New York, 10065, United States

Oklahoma

Stephenson Cancer Center ( Site 0044), Oklahoma City, Oklahoma, 73104, United States

Oregon

Oregon Health & Science University Center for Health & Healing 2- CHH2 ( Site 0060), Portland, Oregon, 97239, United States

Pennsylvania

Allegheny Health Network ( Site 0042), Pittsburgh, Pennsylvania, 15212, United States

Tennessee

Thompson Cancer Survival Center ( Site 0696), Knoxville, Tennessee, 37916, United States

Utah

Utah Cancer Specialists ( Site 0697), Salt Lake City, Utah, 84106, United States

Washington

Cancer Care Northwest - Spokane Valley ( Site 0036), Spokane Valley, Washington, 99216, United States

Wisconsin

University of Wisconsin Hospital and Clinics ( Site 0033), Madison, Wisconsin, 53792, United States

Buenos Aires F.D.

Instituto Medico Alexander Fleming ( Site 0063), Buenos Aires, Buenos Aires F.D., C1426ANZ, Argentina
Fundacion Favaloro ( Site 0061), Ciudad de Buenos Aires, Buenos Aires F.D., C1093AAS, Argentina
Hospital Municipal de Gastroenterologia Dr. Bonorino Udaondo ( Site 0066), Buenos Aires, C1264AAA, Argentina
CEMIC ( Site 0064), Buenos Aires, C1431FWO, Argentina

Bruxelles-Capitale, Region de

UCL Saint Luc ( Site 0162), Brussels, Bruxelles-Capitale, Region de, 1200, Belgium

Oost-Vlaanderen

UZ Gent ( Site 0163), Ghent, Oost-Vlaanderen, 9000, Belgium

Vlaams-Brabant

UZ Leuven ( Site 0161), Leuven, Vlaams-Brabant, 3000, Belgium

West-Vlaanderen

AZ Delta ( Site 0165), Roeselare, West-Vlaanderen, 8800, Belgium

Rio Grande do Sul

ONCOSITE - Centro de Pesquisa Clinica em Oncologia ( Site 0088), Ijuí, Rio Grande do Sul, 98700-000, Brazil
Hospital Nossa Senhora da Conceicao ( Site 0087), Porto Alegre, Rio Grande do Sul, 91350-200, Brazil

Santa Catarina

Clinica de Oncologia Reichow ( Site 0085), Blumenau, Santa Catarina, 89010-340, Brazil
Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0081), São Paulo, 01246-000, Brazil

Alberta

Cross Cancer Institute ( Site 0010), Edmonton, Alberta, T6G 1Z2, Canada

Manitoba

CancerCare Manitoba ( Site 0002), Winnipeg, Manitoba, R3E 0V9, Canada

Ontario

The Ottawa Hospital - Cancer Care ( Site 0008), Ottawa, Ontario, K1H 8L6, Canada
Sunnybrook Research Institute ( Site 0012), Toronto, Ontario, M4N 3M5, Canada
Princess Margaret Cancer Centre ( Site 0011), Toronto, Ontario, M5G 2M9, Canada

Quebec

Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0005), Montreal, Quebec, H2X 0A9, Canada

Region M. de Santiago

Centro de Cancer Nuestra Senora de la Esperanza ( Site 0104), Santiago, Region M. de Santiago, 8330024, Chile

Región de la Araucanía

Centro Investigación del Cáncer James Lind ( Site 0106), Temuco, Región de la Araucanía, 4800827, Chile
Centro de Investigacion y desarrollo Oncologico SpA - CIDO SpA ( Site 0103), Temuco, Región de la Araucanía, 4810218, Chile

Región del Biobío

Hospital Regional de Concepcion ( Site 0105), Concepción, Región del Biobío, 4070038, Chile

Anhui

Anhui Provincial Hospital-Oncology Radiotherapy Department ( Site 0531), Hefei, Anhui, 230071, China

Fujian

The 900th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army ( Si, Fuzhou, Fujian, 350025, China
The First Affiliated Hospital of Xiamen University ( Site 0538), Xiamen, Fujian, 361003, China

Hubei

Hubei Cancer Hospital ( Site 0514), Wuhan, Hubei, 430079, China

Hunan

Hunan Cancer Hospital ( Site 0515), Changsha, Hunan, 410006, China

Jiangsu

Huai an First People s Hospital ( Site 0526), Huai'an, Jiangsu, 223001, China
Jiangsu Cancer Hospital ( Site 0519), Nanjing, Jiangsu, 210000, China
The Affiliated Hospital of Xuzhou Medical University ( Site 0522), Xuzhou, Jiangsu, 221002, China
Affiliated Hospital of Jiangsu University ( Site 0524), Zhenjiang, Jiangsu, 212000, China

Jiangxi

Jiangxi Cancer Hospital ( Site 0512), Nanchang, Jiangxi, 330029, China

Shanghai Municipality

Shanghai Chest Hospital ( Site 0501), Shanghai, Shanghai Municipality, 200030, China
Shanghai Chest Hospital ( Site 0503), Shanghai, Shanghai Municipality, 200030, China
Zhongshan Hospital Fudan University ( Site 0502), Shanghai, Shanghai Municipality, 200032, China

Sichuan

Sichuan Cancer Hospital ( Site 0527), Chengdu, Sichuan, 610041, China

Tianjin Municipality

Tianjin Medical University Cancer Institute & Hospital ( Site 0505), Tianjin, Tianjin Municipality, 300060, China

Zhejiang

Hangzhou First People's Hospital ( Site 0530), Hangzhou, Zhejiang, 310002, China
Sir Run Run Shaw Hospital ( Site 0523), Hangzhou, Zhejiang, 310018, China
Zhejiang Cancer Hospital ( Site 0529), Hangzhou, Zhejiang, 310022, China

Brno-mesto

Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 0721), Brno, Brno-mesto, 656 53, Czechia

Moravskoslezský kraj

Fakultni nemocnice Ostrava-Klinika onkologicka ( Site 0719), Ostrava, Moravskoslezský kraj, 708 52, Czechia

Olomoucký kraj

Fakultni nemocnice Olomouc-Onkologicka klinika ( Site 0720), Olomouc, Olomoucký kraj, 779 00, Czechia

Praha 5

Fakultni nemocnice v Motole-Onkologicka klinika 2. LF UK a FN Motol ( Site 0718), Prague, Praha 5, 150 06, Czechia

Capital Region

Rigshospitalet ( Site 0199), Copenhagen, Capital Region, 2100, Denmark

Region Syddanmark

Odense Universitetshospital ( Site 0200), Odense, Region Syddanmark, 5000, Denmark

Harju

SA Pohja-Eesti Regionaalhaigla ( Site 0201), Tallinn, Harju, 13419, Estonia

Tartu

SA Tartu Ulikooli Kliinikum ( Site 0202), Tartu, Tartu, 50406, Estonia

Ain

Institut De Cancerologie De Lorraine ( Site 0222), Vandœuvre-lès-Nancy, Ain, 54519, France

Calvados

Centre Francois Baclesse ( Site 0236), Caen, Calvados, 14075, France

Cote-d Or

Centre Georges Francois Leclerc ( Site 0223), Dijon, Cote-d Or, 21079, France

Haute-Vienne

CHU Limoges Hopital Dupuytren ( Site 0225), Limoges, Haute-Vienne, 87042, France

Hauts-de-Seine

Institut Curie - Centre Rene Huguenin ( Site 0237), Saint-Cloud, Hauts-de-Seine, 92210, France

Marne

Institut Jean Godinot ( Site 0238), Reims, Marne, 51726 CEDEX, France

Pays de la Loire Region

CHU Hotel Dieu Nantes ( Site 0230), Nantes, Pays de la Loire Region, 44093, France

Provence-Alpes-Côte d'Azur Region

Institut Sainte Catherine ( Site 0228), Avignon, Provence-Alpes-Côte d'Azur Region, 84918, France

Somme

CHU Amiens Picardie Site Sud Amiens ( Site 0235), Amiens, Somme, 80054, France

Vendee

CHD Vendee ( Site 0227), La Roche-sur-Yon, Vendee, 85925, France

Baden-Wurttemberg

Marienhospital Stuttgart Vincenz von Paul Kliniken gGmbH ( Site 0253), Stuttgart, Baden-Wurttemberg, 70199, Germany

North Rhine-Westphalia

Universitaetsklinikum Koeln ( Site 0251), Cologne, North Rhine-Westphalia, 50937, Germany
Universitaetsklinikum Muenster ( Site 0248), Münster, North Rhine-Westphalia, 48149, Germany

Rhineland-Palatinate

Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz ( Site 0247), Mainz, Rhineland-Palatinate, 55131, Germany
Charite Campus Virchow Klinikum ( Site 0250), Berlin, 13353, Germany
Facharztzentrum Eppendorf ( Site 0242), Hamburg, 20249, Germany
Centro de Investigaciones Clinicas de Latinoamerica S.A. - CELAN ( Site 0122), Guatemala City, 01010, Guatemala
Gastrosoluciones ( Site 0126), Guatemala City, 01010, Guatemala
Oncomedica ( Site 0125), Guatemala City, 01010, Guatemala
Grupo Medico Angeles ( Site 0121), Guatemala City, 01015, Guatemala
Medi-K Cayala ( Site 0124), Guatemala City, 01016, Guatemala
Centro Medico Integral De Cancerología (CEMIC) ( Site 0123), Quetzaltenango, 09002, Guatemala
Pamela Youde Nethersole Eastern Hospital ( Site 0543), Hong Kong, Hong Kong
Princess Margaret Hospital. ( Site 0542), Hong Kong, Hong Kong
Queen Mary Hospital ( Site 0541), Pokfulam, Hong Kong

Baranya

Pecsi Tudomanyegyetem AOK ( Site 0265), Pécs, Baranya, 7624, Hungary

Bekes County

Bekes Megyei Kozponti Korhaz - Pandy Kalman Tagkorhaza ( Site 0262), Gyula, Bekes County, 5700, Hungary
Orszagos Onkologiai Intezet ( Site 0263), Budapest, 1122, Hungary
Debreceni Egyetem Klinikai Kozpont ( Site 0261), Debrecen, 4032, Hungary

Lombardy

Fondazione IRCCS Policlinico San Matteo-Oncology ( Site 0300), Pavia, Lombardy, 27100, Italy

Milano

IRCCS Policlinico San Donato ( Site 0295), San Donato Milanese, Milano, 20097, Italy

Tuscany

Azienda Ospedaliero Universitaria Pisana - Presidio Santa Chiara ( Site 0294), Pisa, Tuscany, 56126, Italy
ASST Papa Giovanni XXIII ( Site 0296), Bergamo, 24127, Italy
Azienda Socio Sanitaria Territoriale di Cremona ( Site 0299), Cremona, 26100, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 0292), Milan, 20133, Italy
Istituto Nazionale Tumori IRCCS Fondazione Pascale-SC Oncologia Clinica Sperimentale Addome ( Site 0, Naples, 80131, Italy
IRCCS Istituto Oncologico Veneto ( Site 0298), Padua, 35128, Italy
Policlinico Universitario A. Gemelli ( Site 0297), Roma, 00168, Italy

Aichi-ken

Aichi Cancer Center Hospital ( Site 0563), Nagoya, Aichi-ken, 464-8681, Japan

Chiba

National Cancer Center Hospital East ( Site 0562), Kashiwa, Chiba, 2778577, Japan

Kanagawa

Kanagawa Cancer Center ( Site 0565), Yokohama, Kanagawa, 241-8515, Japan

Saitama

Saitama Cancer Center ( Site 0564), Kitaadachi-gun, Saitama, 362-0806, Japan

Shizuoka

Shizuoka Cancer Center Hospital and Research Institute ( Site 0566), Sunto-gun, Shizuoka, 411-8777, Japan
National Cancer Center Hospital ( Site 0561), Tokyo, 104-0045, Japan

Mexico City

Cryptex Investigación Clínica S.A. de C.V. ( Site 0729), Cuauhtémoc, Ciudad de México, Mexico City, 06100, Mexico
CENTRO HEMATO ONCOLOGICO PRIVADO-CHOP ( Site 0728), Toluca, 50120, Mexico

Muni Metro de Lima

Instituto Nacional de Enfermedades Neoplasicas ( Site 0141), Lima, Muni Metro de Lima, Lima 34, Peru
Detecta Clínica ( Site 0146), Surquillo, Muni Metro de Lima, 15038, Peru
Hospital Nacional Arzobispo Loayza ( Site 0143), Lima, 15082, Peru
Clinica San Gabriel ( Site 0142), Lima, 15087, Peru

Benguet

Baguio General Hospital and Medical Center ( Site 0603), Baguio City, Benguet, 2600, Philippines

Cebu

Cebu Doctors University Hospital ( Site 0604), Cebu City, Cebu, 6000, Philippines

Iloilo

The Medical City-Iloilo ( Site 0602), Iloilo City, Iloilo, 5000, Philippines

National Capital Region

St. Luke s Medical Center ( Site 0601), Quezon City, National Capital Region, 1102, Philippines

Lisbon District

Hospital Beatriz Angelo ( Site 0374), Loures, Lisbon District, 2674-514, Portugal
Inst. Portugues de Oncologia de Lisboa Francisco Gentil EPE ( Site 0372), Lisbon, 1099-023, Portugal
Hospital da Luz ( Site 0373), Lisbon, 1500 650, Portugal
CHLN Hospital Santa Maria ( Site 0376), Lisbon, 1649-035, Portugal
Inst. Portugues de Oncologia de Porto Francisco Gentil EPE ( Site 0371), Porto, 4200-072, Portugal

București

MedEuropa Bucuresti - Centru de Radioterapie-Oncology ( Site 0400), Bucharest, București, 022343, Romania

Cluj

Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 0392), Cluj-Napoca, Cluj, 400015, Romania
S.C. Radiotherapy Center Cluj S.R.L ( Site 0391), Cluj-Napoca, Cluj, 407280, Romania

Constanța County

Ovidius Clinical Hospital OCH-Oncology and Hematology ( Site 0393), Ovidiu, Constanța County, 905900, Romania

Dolj

S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 0394), Craiova, Dolj, 200542, Romania

Mureș County

Centrul Medical Topmed ( Site 0398), Târgu Mureş, Mureș County, 540156, Romania
S.C.Focus Lab Plus S.R.L ( Site 0395), Bucharest, 022548, Romania

Baskortostan, Respublika

GBUZ Republican Clinical Oncological Dispensary-Antitumor drug therapy department ( Site 0430), Ufa, Baskortostan, Respublika, 450054, Russia

Kaluzskaja Oblast

Kaluga Regional Clinical Oncology Center ( Site 0424), Kaluga, Kaluzskaja Oblast, 248007, Russia

Moscow

Main Military Clinical Hospital n.a. N.N.Burdenko ( Site 0421), Moscow, Moscow, 105229, Russia
FSAI Treatment and Rehabilitation Centre of the MoH and SD of RF ( Site 0429), Moscow, Moscow, 125367, Russia

Samara Oblast

SBHI Samara Regional Clinical Oncology Dispensary ( Site 0420), Samara, Samara Oblast, 443031, Russia

Sankt-Peterburg

Pavlov First Saint Petersburg State Medical University ( Site 0426), Saint Petersburg, Sankt-Peterburg, 197022, Russia
Medical institute named after Berezin Sergey ( Site 0417), Saint Petersburg, Sankt-Peterburg, 197758, Russia

Sverdlovsk Oblast

Sverdlovsk Regional Oncology Hospital ( Site 0411), Yekaterinburg, Sverdlovsk Oblast, 620036, Russia

Tatarstan, Respublika

Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 0412), Kazan', Tatarstan, Respublika, 420029, Russia
Chang Gung Med Foundation. Kaohsiung Branch ( Site 0643), Kaohsiung City, 833, Taiwan
China Medical University Hospital ( Site 0646), Taichung, 40447, Taiwan
Taichung Veterans General Hospital-Radiation Oncology ( Site 0647), Taichung, 407, Taiwan
National Cheng Kung University Hospital ( Site 0645), Tainan, 70457, Taiwan
National Taiwan University Hospital ( Site 0641), Taipei, 10002, Taiwan
Koo Foundation Sun Yat-Sen Cancer Center ( Site 0644), Taipei, 11259, Taiwan
Chang Gung Medical Foundation. Linkou ( Site 0642), Taoyuan District, 33305, Taiwan

Istanbul

Istanbul University Cerrahpasa Medical Faculty ( Site 0452), Istanbul, Istanbul, 34098, Turkey (Türkiye)
Memorial Ankara Hastanesi ( Site 0461), Ankara, 06520, Turkey (Türkiye)
Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi-oncology ( Site 0451), Istanbul, 34722, Turkey (Türkiye)
Ege Universitesi Tip Fakultesi ( Site 0457), Izmir, 35040, Turkey (Türkiye)
Izmir Katip Celebi Universitesi Ataturk Egitim ve Arastirma Hastanesi ( Site 0458), Izmir, 35360, Turkey (Türkiye)

Aberdeen City

Aberdeen Royal Infirmary ( Site 0474), Aberdeen, Aberdeen City, AB25 2ZN, United Kingdom

Cambridgeshire

Cambridge University Hospitals NHS Trust ( Site 0477), Cambridge, Cambridgeshire, CB2 0QQ, United Kingdom

England

Royal Free Hospital ( Site 0702), London, England, NW32QG, United Kingdom

London, City of

ROYAL MARSDEN HOSPITAL (CHELSEA) ( Site 0283), London, London, City of, SW3 6JJ, United Kingdom
Hammersmith Hospital-Medical Oncology ( Site 0471), London, London, City of, W12 OHS, United Kingdom

Nottinghamshire

Nottingham University Hospitals NHS Trust ( Site 0476), Nottingham, Nottinghamshire, NG5 1PB, United Kingdom

Surrey

Royal Marsden Hospital (Sutton) ( Site 0281), Sutton, Surrey, SM2 5PT, United Kingdom

Worcestershire

University College Hospital NHS Foundation Trust ( Site 0701), London, Worcestershire, NW1 2PG, United Kingdom
The Christie NHS Foundation Trust ( Site 0282), Manchester, M20 4BX, United Kingdom
Mount Vernon Hospital ( Site 0478), Northwood, HA6 2RN, United Kingdom